Fuller & Thaler Asset Management
ACOR

Fuller & Thaler Asset Management’s Acorda Therapeutics ACOR Stock Holding History

Fuller & Thaler Asset Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-18
Closed -$69K – 746
2013
Q2 		$69K Buy
+18
New +$74.1K ﹤0.01% 546

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fuller & Thaler Asset Management's ACOR Position: Q3 2013 in Review

Fuller & Thaler Asset Management sold out of Acorda Therapeutics (ACOR) in Q3 2013, closing a stake of 18 shares — an estimated $69K sold.

Fuller & Thaler Asset Management first reported a position in ACOR in Q2 2013 and held it in 1 quarter. The position peaked at $69K in Q2 2013. 153 funds tracked by Wall St. Rank hold ACOR as of Q3 2013.

  • Fuller & Thaler Asset Management reported no remaining Acorda Therapeutics position as of Q3 2013 after selling out during the quarter.
  • Fuller & Thaler Asset Management sold 18 Acorda Therapeutics shares in Q3 2013, an estimated $69K.
  • Fuller & Thaler Asset Management first reported a position in Acorda Therapeutics in Q2 2013 and held it in 1 quarter.
  • Fuller & Thaler Asset Management's Acorda Therapeutics position peaked at $69K in Q2 2013.
  • 153 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2013.

Based on Fuller & Thaler Asset Management's 13F filing for Q3 2013, filed 12 Nov 2013.